GlassScriptPhysician profile
Robert Malovany
NPI 1255355400
$5,042.86
in general payments reported to CMS, 2019-2025
54 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $455 · 2021: $617 · 2022: $801 · 2023: $876 · 2024: $378 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,275.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.32 | 2019-2024 | Ofev, Spiriva Respimat |
| Amgen INC. | $285.33 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Merck Sharp & Dohme LLC | $275.24 | 2019-2025 | Keytruda, Capvaxive |
| Mallinckrodt Hospital Products INC. | $229.29 | 2020-2025 | Acthar |
| Genzyme Corporation | $208.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $188.52 | 2019-2025 | Dupixent |
| Novo Nordisk INC | $165.11 | 2019-2021 | |
| Pulmonx Corporation | $149.58 | 2022 | |
| Pfizer INC. | $136.71 | 2019-2025 | |
| Ucb, INC. | $132.84 | 2022-2025 | Bimzelx, Cimzia |
| Grifols USA, LLC | $123.02 | 2020-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $118.94 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $112.28 | 2019-2024 | Airsupra, Tezspire, Breztri |
| Mylan Specialty L.P. | $110.26 | 2019-2024 | Yupelri |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Malovany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.